Purpose: Oxidative stress, which is most likely a key mediator in the development of cardiovascular disease, is implicated in the progression and deterioration of chronic kidney disease. Patients on hemodialysis exhibit the excessive generation of oxidative stressors, which may also be responsible for the endothelial dysfunction prevalent in these patients. Febuxostat, an inhibitor of xanthine oxidase enzyme, is emerging as a novel drug in the amelioration of oxidative stress status. However, studies regarding its effect among hemodialysis patients are still lacking.
Methods: This prospective, block-randomized, double-blinded, placebo-controlled study was carried out to assess the effect of oral 40 mg febuxostat on oxidative stress in hemodialysis patients. In total, fifty-seven eligible patients were randomly assigned to either a drug group or a placebo group for the 2-month study period. Serum malondialdehyde (MDA) and serum superoxide dismutase (SOD) were assessed at baseline and at the end of the study. A correlation analysis between previously reported serum asymmetric dimethylarginine (ADMA), serum MDA and serum SOD was performed.
Results: Febuxostat significantly decreased the serum MDA and significantly increased the serum SOD, while no significant results were observed in the placebo group. A highly positive correlation between the MDA levels and ADMA levels at baseline was noticed in both groups, while there was a highly negative correlation between the SOD levels and ADMA levels at baseline in both groups. A positive correlation between the change in ADMA levels and MDA levels from baseline was observed only in the drug group.
Conclusion: Febuxostat appears to have a direct ameliorating effect on oxidative stress in hemodialysis patients with endothelial dysfunction.
Keywords: Clinical trial; Endothelial dysfunction; Febuxostat; Hemodialysis; Oxidative stress.
Effect of Febuxostat on the Endothelial Dysfunction in Hemodialysis Patients: A Randomized, Placebo-Controlled, Double-Blinded StudyM Alshahawey et al. Am J Nephrol 45 (5), 452-459. PMID 28463849. - Randomized Controlled TrialFebuxostat appears to improve hyperuricemia and endothelial dysfunction and ameliorate inflammation in hemodialysis patients with no safety concerns.
Febuxostat Attenuates Paroxysmal Atrial Fibrillation-Induced Regional Endothelial DysfunctionY Li et al. Thromb Res 149, 17-24. PMID 27865966.Endothelial dysfunction (TM, VWF, ADMA), TAT generation and oxidative stress (XO, SOD, MDA) in group P were more significant compared with that in group S (p<0.05, res …
Febuxostat Improves Endothelial Function in Hemodialysis Patients With Hyperuricemia: A Randomized Controlled StudyY Tsuruta et al. Hemodial Int 19 (4), 514-20. PMID 25998500. - Randomized Controlled TrialEndothelial dysfunction is often found in both hyperuricemia and hemodialysis patients. Recent studies have shown that treating hyperuricemia with allopurinol improves en …
Allopurinol for Chronic GoutR Seth et al. Cochrane Database Syst Rev (10), CD006077. PMID 25314636. - ReviewOur review found low- to moderate-quality evidence indicating similar effects on withdrawals due to AEs and SAEs and incidence of acute gout attacks when allopurinol (100 …
Febuxostat for Treating Chronic GoutJH Tayar et al. Cochrane Database Syst Rev 11, CD008653. PMID 23152264. - ReviewAlthough the incidence of gout flares requiring treatment may be increased in patients taking febuxostat compared to placebo or allopurinol during early treatment, no suc …